Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB201 plus paclitaxel and low-dose gemcitabine vs gemcitabine-based regimens in metastatic pancreatic adenocarcinoma after failure of first-line therapy
CTR20180947Phase 3Active
- Sponsor
- 1Globe Health Institute
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of napabucasin in pancreatic adenocarcinoma (PDAC), sponsored by 1Globe Health Institute. Started Oct 2018; status: active.
02
Drugs
napabucasin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20180947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180947.